OUR STORY
Born from clinical reality. Forged by research.
WundrME™ was born from clinical reality: for patients with mild to moderate eczema, care relies largely on symptomatic treatments, including topical corticosteroids. But needs go beyond symptom control: many also look for skincare suited to daily use and approaches that take the balance of the skin microbiome into account. It is in this perspective that WundrME™ was developed.
Created by a dermatologist
First-of-its-kind formula
5 years of R&D
Made in Germany
THE ORIGIN
When the clinic isn't enough
The story behind WundrME™
For many years, Dr Natalia Kirsten cared for hospital patients living with inflammatory skin conditions. Today, dermatology has modern, effective therapies, particularly for severe forms.
However, among many patients with mild to moderate eczema, one request came up again and again: better-tolerated alternatives to cortisone, suitable for daily use, and above all an approach that does not stop at temporarily soothing symptoms, but looks at the skin's underlying imbalance.
That clinical reality convinced her that the way we approach skin inflammation needed rethinking: going beyond immediate relief to act on the fundamental mechanisms behind a fragile skin barrier and microbiome.
She then devoted five years of research to developing a technology that preserves the benefits of probiotics while making them more stable, safer and better suited to sensitive skin. This is how WundrME™ was born: a new generation of paraprobiotic dermo-cosmetic care, grounded in clinical experience and scientific research.
We kept giving antibiotics, but fundamentally it wasn't working. Resistance kept growing. I thought: there have to be alternatives.
5 YEARS OF R&D
From the lab to your skin
The path that led to a first-of-its-kind paraprobiotic cream.
The clinical realisation.
After years of dealing with chronic ulcers and resistant infections in a German hospital, Natalia launches a research project on alternatives to antibiotics with Ron, a health economist based in the United States.
The probiotic lead
Partnership with laboratories in England. First tests with live probiotics against skin pathogens. The results are promising — but problems emerge.
The turning point
Analysis of probiotic consumption data across 60 countries: live probiotics can trigger antibiotic resistance. On top of that, regulatory costs for a medical product would reach €8–12M. Dead end.
The decisive pivot
Natalia develops a method to inactivate probiotics while keeping their structure intact — under the electron microscope, a live cell is indistinguishable from a treated one. More effective than live cultures, without the risks.
A first-of-its-kind formula
Testing confirms the stability of the process and its action on skin microbiome balance. No equivalent technology exists on the market today.
EU regulatory approval
Testing has given us the basis to protect our formula and to qualify it as a dermo-cosmetic (health and beauty).
Launch in France and the United Kingdom
Manufactured in Germany to pharmaceutical standards. The first-of-its-kind paraprobiotic cream that rebalances the microbiome is sold through the WundrME™ e-commerce platform.
TECHNOLOGY
What no other cream can do
“Probiotic” creams contain live bacteria that die on contact with preservatives. WundrME™ uses paraprobiotics.
First-of-its-kind structural preservation
Under the electron microscope, a live cell is indistinguishable from one treated with our process.
Binding to skin receptors
Paraprobiotics bind to the skin's receptors and limit the adhesion of pathogens (in vitro test).
Stability and safety
Unlike live probiotics, no risk of proliferation. Compatible with cosmetic preservatives.
TECHNOLOGY
What no other cream can do
“Probiotic” creams contain live bacteria that die on contact with preservatives. WundrME™ uses paraprobiotics.
Dr Natalia Kirsten
Dermatologist and scientist – Founder of WundrME™
Natalia Kirsten is not an influencer launching a cosmetics brand. She is a dermatologist and scientist, from a family of doctors, who ran a hospital department in Germany and supervised clinical studies for years before developing WundrME™.
“I spent five years developing a method to make probiotics more stable and safer than their live equivalents. WundrME™ came out of that.”
